 |
|
Ireland Cancer Center researchers advance stem cell gene therapy
December 13, 2007Researchers present findings at American Society of Hematology Meeting
Ireland Cancer Center of University Hospitals Case Medical Center researchers have recently made great strides in stem cell gene therapy research by transferring a new gene to cancer patients, via their own stem cells, with the ultimate goal of being able to use stronger chemotherapy treatment with less severe side effects. Under this protocol, MGMT, a drug-resistance gene, is added into purified hematopoietic stem cells to protect these cells from the damage of chemotherapy regimens.
In one of 24 presentations by Ireland Cancer Center researchers at the annual American Society of Hematology meeting, Stanton Gerson, MD, and colleagues presented that eight patients were enrolled on the trial and six were infused with their own stem cells which were engineered to carry the MGMT gene. In three patients, stem cells carrying the gene were identified in their blood or bone marrow. In one patient, stem cells carrying the gene were detected up to 28 weeks after their administration. This significant finding has never been reported before with this gene and drug combination.
¡§This study is the first to show the success of treatment with evidence that stem cells now carry the new gene,¡® says Dr. Gerson, Director of the Ireland Cancer Center and Case Comprehensive Cancer Center, who spearheaded the Phase I study along with a team of researchers. ¡§These patients show the success of treatment with evidence that their stem cells now carry the new genes. This is a breakthrough ¡V the first time selection with MGMT has been shown to occur in patients.¡®
Preclinical animal research, conducted by Dr. Gerson and his colleagues, has shown that the gene G156A-MGMT can provide stem cells with very high levels of drug resistance, compared to normal stem cells not carrying the gene. In the Phase I trial for patients with advanced malignancies, researchers collected peripheral blood stem cells from patients and exposed them to a retrovirus containing the G156A-MGMT gene.
In addition to this promising research, Ireland Cancer Center scientists presented 24 oral and poster presentations at ASH. ¡§The breadth and depth of this innovative hematologic research at the Ireland Cancer Center are outstanding,¡® says Alvin Schmaier, MD, Chief of Hematology/Oncology at UHCMC and Case Western Reserve University School of Medicine. ¡§Our faculty is making tremendous advances in these fields which is reflected in their being chosen for oral and poster presentations.¡®
The presentations include:
* Dr. Hillard Lazarus and colleagues presented significant findings that treatment with Rituximab before transplantation results in cure rate and overall survival in patients undergoing autologous stem cell transplantation for Diffuse Large B-Cell lymphoma.
* Dr. Lazarus and colleagues of the Eastern Cooperative Oncology Group (ECOG) presented data that show that Imatninib (Gleevec) does not change outcomes on patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia.
* Dr. Lazarus presented an assessment of data over 30 years regarding acute leukemia and its management. He found that all avenues lead to stem cell transplantations. His team provided this assessment of a whole host of entities that provide leukemia care.
* Dr. Jonathan Kenyon and colleagues found that normal individuals over age 50 begin to show evidence that genetic mutations are accumulating in marrow stem cells. This finding might be the key underlying the increased risk of anemias, myelodysplastic syndrome and acute leukemia in older individuals.
* Dr. Kevin Bunting¡¦s laboratory gave two important presentations on how intracellular STAT5 (an intracellular signaling protein) influences normal pathologic hematopoiesis (blood cell formation) and stem cell engraftment.
* Dr. Shigemi Matsuyama and colleagues presented a novel way of treating chemotherapy -induced thrombocytopenia (decrease in number of platelets in the blood) using Bax Inhibiting Peptides to rescue the damaged cells.
* Dr. Keith McCrae and colleagues presented that ƒ"2 glycoprotein is a cofactor in the process that dissolves blood clots through the use of the medical agent tPA.
University Hospitals of Cleveland
¡§This study is the first to show the success of treatment with evidence that stem cells now carry the new gene,¡® says Dr. Gerson, Director of the Ireland Cancer Center and Case Comprehensive Cancer Center, who spearheaded the Phase I study along with a team of researchers. ¡§These patients show the success of treatment with evidence that their stem cells now carry the new genes. This is a breakthrough ¡V the first time selection with MGMT has been shown to occur in patients.¡®
Preclinical animal research, conducted by Dr. Gerson and his colleagues, has shown that the gene G156A-MGMT can provide stem cells with very high levels of drug resistance, compared to normal stem cells not carrying the gene. In the Phase I trial for patients with advanced malignancies, researchers collected peripheral blood stem cells from patients and exposed them to a retrovirus containing the G156A-MGMT gene.
In addition to this promising research, Ireland Cancer Center scientists presented 24 oral and poster presentations at ASH. ¡§The breadth and depth of this innovative hematologic research at the Ireland Cancer Center are outstanding,¡® says Alvin Schmaier, MD, Chief of Hematology/Oncology at UHCMC and Case Western Reserve University School of Medicine. ¡§Our faculty is making tremendous advances in these fields which is reflected in their being chosen for oral and poster presentations.¡®
The presentations include:
* Dr. Hillard Lazarus and colleagues presented significant findings that treatment with Rituximab before transplantation results in cure rate and overall survival in patients undergoing autologous stem cell transplantation for Diffuse Large B-Cell lymphoma.
* Dr. Lazarus and colleagues of the Eastern Cooperative Oncology Group (ECOG) presented data that show that Imatninib (Gleevec) does not change outcomes on patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia.
* Dr. Lazarus presented an assessment of data over 30 years regarding acute leukemia and its management. He found that all avenues lead to stem cell transplantations. His team provided this assessment of a whole host of entities that provide leukemia care.
* Dr. Jonathan Kenyon and colleagues found that normal individuals over age 50 begin to show evidence that genetic mutations are accumulating in marrow stem cells. This finding might be the key underlying the increased risk of anemias, myelodysplastic syndrome and acute leukemia in older individuals.
* Dr. Kevin Bunting¡¦s laboratory gave two important presentations on how intracellular STAT5 (an intracellular signaling protein) influences normal pathologic hematopoiesis (blood cell formation) and stem cell engraftment.
* Dr. Shigemi Matsuyama and colleagues presented a novel way of treating chemotherapy -induced thrombocytopenia (decrease in number of platelets in the blood) using Bax Inhibiting Peptides to rescue the damaged cells.
* Dr. Keith McCrae and colleagues presented that ƒ"2 glycoprotein is a cofactor in the process that dissolves blood clots through the use of the medical agent tPA.
University Hospitals of Cleveland
Stem Cell Current Events and Stem Cell News RSSFirst use of antibody and stem cell transplantation to successfully treat advanced leukemia
For the first time, researchers at Fred Hutchinson Cancer Research Center have reported the use of a radiolabeled antibody to deliver targeted doses of radiation, followed by a stem cell transplant, to successfully treat a group of leukemia and pre-leukemia patients for whom there previously had been no other curative treatment options.
Immune therapy can protect against or treat later lymphoma
Specially developed immune system cells that target the common Epstein-Barr virus can protect immune-suppressed bone marrow transplant recipients against lymph system disease and cancers that arise from the viral infection.
Immunotherapy demonstrates long-term success in treating lymphoma
Targeted immunotherapy has been an attractive new therapeutic area for a number of cancers because it has the potential to destroy tumor cells without damaging surrounding normal tissue. New study results demonstrate high success rates using specialized white blood cells to prevent or treat lymphoma associated with the Epstein-Barr virus (EBV-lymphoma) in patients who have received a hematopoietic stem cell transplant (HSCT).
Of mice and men: Stem cells and ethical uncertainties
The recent creation of live mice from induced pluripotent stem cells (iPSCs) not only represents a remarkable scientific achievement, but also raises important issues, according to bioethicists at The Johns Hopkins University's Berman Institute of Bioethics.
Stem cell therapy may offer hope for acute lung injury
Researchers at the University of Illinois at Chicago College of Medicine have shown that adult stem cells from bone marrow can prevent acute lung injury in a mouse model of the disease.
Placental precursor stem cells require testosterone-free environment to survive
Trophoblast stem cells (TSCs), cells found in the layer of peripheral embryonic stem cells from which the placenta is formed, are thought to exhibit "immune privilege" that aids cell survivability and is potentially beneficial for cell and gene therapies.
Endocrine Society calls for expanded scope and funding for stem cell research
Stem cell research holds great promise for the treatment of millions of Americans with debilitating and possibly fatal diseases.
Scientists develop novel method to generate functional hepatocytes for drug testing
Scientists have for the first time produced liver cells from adult skin cells using the induced pluripotent stem cell (iPSC) technology.
Researchers find ways to encourage spinal cord regeneration after injury
Animal research is suggesting new ways to aid recovery after spinal cord injury. New studies demonstrate that diet affects recovery rate and show how to make stem cell therapies safer for spinal injury patients.
Experimental treatments restore partial vision to blind people
Two experimental treatments, a retinal prosthesis and fetal tissue transplant, restored some vision to people with blinding eye diseases. The findings, presented at Neuroscience 2009, the annual meeting of the Society for Neuroscience and the world's largest source of emerging news on brain science and health, may lead to new treatments for the blind.
More Stem Cell Current Events and Stem Cell News Articles
 |
Essentials of Stem Cell Biology, Second Edition by Robert Lanza (Editor), John Gearhart (Editor), Brigid Hogan (Editor), Douglas Melton (Editor), Roger Pederson (Editor), E. Donnall Thomas (Editor), James Thomson (Editor), Sir Ian Wilmut (Editor) First developed as an accessible abridgement of the successful Handbook of Stem Cells, Essentials of Stem Cell Biology serves the needs of the evolving population of scientists, researchers, practitioners and students that are embracing the latest advances in stem cells. Representing the combined effort of seven editors and more than 200 scholars and scientists whose pioneering work has defined our understanding of stem cells, this book combines the prerequisites for a general understanding of adult and embryonic stem cells with a presentation by the world?s experts of the latest research information about specific organ systems. From basic biology/mechanisms, early development, ectoderm, mesoderm, endoderm, methods to application of stem cells to specific human diseases, regulation and... |
 |
The Stem Cell Divide: The Facts, the Fiction, and the Fear Driving the Greatest Scientific, Political, and Religious Debate of Our Time by Michael Bellomo (Author) There has been much recent debate about the merits, dangers, and nature of stem cell research. Some see in it the answer to every debilitating disease known to man, while others see it as a step away from human cloning. While the battle has raged, research is moving ahead, and California has already passed a measure that will give $3 billion in support to stem cell research. But as politics, religion, and the media weigh in on this complex issue, more and more of the scientific reality of stem cell research is getting lost. In the search for the truth about stem cell science, the author has interviewed the scientists whose cutting-edge research is at the very heart of this hot-button issue. The book explains what they have accomplished so far, what they're currently doing, and what... |
 |
Stem Cell Now by Christopher Thomas Scott (Author) The essential account of the most important scientific advance—and most volatile ethical debate—of our time While many believe stem cell research holds the key to curing a wide range of ailments, others see this research as opening a Pandora’s box that will devalue human life. In Stem Cell Now, Christopher Scott—executive director of Stanford University’s Stem Cells and Society Program—lays out the scientific and ethical issues surrounding this national dilemma. Scott guides readers through the latest advances in stem cell research in clear, accessible language, telling the stories of the researchers who are exploring the potential of stem cells to cure cancer, grow new organs, and repair the immune system. He also leads readers through a... |
 |
Stem Cell Research: Medical Applications And Ethical Controversy (The New Biology) by Joseph, Ph.D. Panno (Author) This is an informative reference to the technological advances, applications, and issues of stem cell research. The past few years have seen controversy and debate surrounding stem cell research. Because skin cells have the capability to divide - unlike most of the cells in our body - our skin can heal itself through the division of cells. Scientists have attempted to apply this concept to major organs, trying to see if stem cells can be used to make the repairs that post-mitotic cells cannot. "Stem Cell Research" is a comprehensive and interesting introduction to this popular new science for non-experts. Explaining how stems cells can be obtained from several places, including skin, bone marrow, and most usefully, embryos, this book covers all the fundamental aspects of stem cell... |
 |
Human Stem Cell Manual: A Laboratory Guide by Jeanne F. Loring (Editor), Robin L. Wesselschmidt (Editor), Philip H. Schwartz (Editor) Stem cells are self-replicating and undifferentiated, meaning their function is not yet cell, tissue, or organ-specific. Due to the unique nature of these cells, research into their biology and function holds great promise for therapeutic applications through replacement or repair of diseased and damaged cells. This reader-friendly manual provides a practical "hands on" guide to the culture of human embryonic and somatic stem cells. By presenting methods for embryonic and adult lines side-by-side, the authors lay out an elegant and unique path to understanding the science of stem cell practice. The authors begin with a broad-based introduction to the field, and also review legal and regulatory issues and patents. Each experimental strategy is presented with an historical introduction,... |
 |
Stem Cell Medicine: The New Adult Stem Cell Regenerative Therapy for Cancer, Spinal Injuries, Multiple Sclerosis, Parkinson's and other conditions. by Robin Smith MD MBA (Author), Suzanne Somers (Foreword) Unlock the Power of Your Own Cells Stem Cell Medicine gives an authoritive, comprehensive and understandable "crash course" in this important scientific technology, and explains how the adult stem cell--extracted from patients' own bodies--offers incredible curative possibilities, without political controversy. As a primitive cell that call transform into many different types of cells, the adult stem cell can be used to combat a variety of diseases, including multiple sclerosis, heart disease, cancer, leukemia and Lupus. Real-life sucess stories prove that this technology that seems "too good to be true" is actually changing lives. In addition to presenting remarkable evidence and true stories of stem cells treating and, in many cases, curing diseases, Stem Cell... |
 |
Cell of Cells: The Global Race to Capture and Control the Stem Cell by Cynthia Fox (Author) Publication Date is March 26, 2007 |
 |
The Stem Cell Dilemma: Beacons of Hope or Harbingers of Doom? by Leo Furcht (Author), William Hoffman (Author) TodayÕs scientists are showing us how stem cells create and repair the human body. Unlocking these secrets has become the new Holy Grail of biomedical research. But behind that search lies a sharp divide. Stem cells offer the hope of creating or repairing tissues lost to age, disease, and injury. Yet because of this ability, stem cells hold the potential to incite an international biological arms race. THE STEM CELL DILEMMA will tell you everything you ever wanted to know about stem cells: what they are, how they work, and why their use has become so controversial. We are standing at a scientific crossroads, the likes of which the world has never seen. It is a moment that will change forever the practice of medicine and the future of life as we know it. |
 |
Mesenchymal Stem Cells: Methods and Protocols (Methods in Molecular Biology) by Darwin J. Prockop (Editor), Donald G. Phinney (Editor), Bruce A. Bunnell (Editor) For over forty years, mesenchymal stem cells (MSCs) have been scrutinized and studied, garnering much attention due to their broad therapeutic efficacy. In Mesenchymal Stem Cells: Methods and Protocols, leaders in the field were assembled to contribute detailed methodologies for the isolation and characterization of human and rodent MSCs. Recently, these vital cells have shown therapeutic benefits in the treatment of myocardial infarction, stroke, lung diseases, spinal cord injury and other neurological disorders, thus promising a boundless future in their study. Cutting edge and easy to use, Mesenchymal Stem Cells: Methods and Protocols is the perfect resource for scientists attempting to pursue this important and ever-developing field of research. |
 |
Swiss Apple Stem Cell Serum by Emerge Labs Stem Cell Skin Care SerumTM Emerge Labs presents a revolutionary technology that protects skin stem cells and combats chronological aging. The breakthrough patent pending active ingredient, PhytoCellTec Malus Domsestica, boosts the production of human skin stem cells, protects human skin stem cells from stress, thus decreasing wrinkles and producing younger, fresher looking skin. Using a novel, patent-pending plant cell culture technology, Emerge Labs introduces PhytoCellTec - dedifferentiated callus cells from a rare Swiss apple that studies show protect skin stem cells thus promoting self-renewal capacity of the skin. Apple stem cells are rich in epigenetic factors and metabolites that assure the longevity of skin cells. The application of plant cell cultures to maintain the function... |
| © 2009 BrightSurf.com |